🔎 Trials Near Me

Home › Kanser sa Prostate › Illinois › Peoria

Pag-aaral pangklinika para sa Kanser sa Prostate sa Peoria, IL

9 pag-aaral para sa Kanser sa Prostate ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Peoria (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Nagre-recruitPhase 3
  • Illinois CancerCare-Peoria, Peoria
  • Illinois CancerCare-Pekin, Pekin · 9 mi ang layo
  • Illinois CancerCare-Canton, Canton · 25 mi ang layo
Edad 18 pataas · Kalalakihan · Na-update Okt 2, 2026 · NCT06931340

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Illinois CancerCare-Peoria, Peoria
  • Methodist Medical Center of Illinois, Peoria
  • Illinois CancerCare-Pekin, Pekin · 9 mi ang layo
  • at 1 pa
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Nagre-recruitPhase 2
  • Illinois CancerCare-Peoria, Peoria
  • Illinois CancerCare-Pekin, Pekin · 9 mi ang layo
  • Illinois CancerCare-Canton, Canton · 25 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06632977

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Nagre-recruitPhase 3
  • Illinois Cancer Care ( Site 0104), Peoria
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06136650

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Nagre-recruitPhase 3
  • OSF Saint Francis Medical Center, Peoria
  • Illinois CancerCare-Pekin, Pekin · 9 mi ang layo
Edad 18 pataas · Kalalakihan · Na-update Set 10, 2026 · NCT05946213

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Nagre-recruitPhase 3
  • Illinois CancerCare-Peoria, Peoria
  • Methodist Medical Center of Illinois, Peoria
  • Illinois CancerCare-Pekin, Pekin · 9 mi ang layo
  • at 1 pa
Edad 18 pataas · Kalalakihan · Na-update Ago 19, 2026 · NCT04423211

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Nagre-recruitPhase 3
  • Illinois CancerCare-Peoria, Peoria
  • Methodist Medical Center of Illinois, Peoria
  • Illinois CancerCare-Pekin, Pekin · 9 mi ang layo
  • at 1 pa
Edad 18 pataas · Kalalakihan · Na-update Ene 22, 2026 · NCT06470243

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Nagre-recruitPhase 4
  • Methodist Medical Center of Illinois, Peoria
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Ene 22, 2026 · NCT04373564

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Nagre-recruitPhase 3
  • Illinois CancerCare-Peoria, Peoria
  • Methodist Medical Center of Illinois, Peoria
  • OSF Saint Francis Medical Center, Peoria
  • at 2 pa
Edad 18 pataas · Kalalakihan · Na-update Set 11, 2025 · NCT03678025

Pag-aaral para sa Kanser sa Prostate sa ibang lungsod

Iba pang pag-aaral sa Peoria

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.